Remove 2026 Remove Healthcare Remove Prescription
article thumbnail

The continued shame of pharma

World of DTC Marketing

Nationwide, prescription drug spending last year is estimated to be $328 billion among all payers, including private insurance, Medicare Part D, and patients’ out-of-pocket expenses. Nearly 9 in 10 older adults take prescription medication. Still, the pharma industry is fighting hard to keep it off the table.

Pharma 256
article thumbnail

Health consumers: A long way off

World of DTC Marketing

We keep hearing the term “consumers of health” but the American healthcare system is too profitable to allow people to be consumers of healthcare. What if … people got a fair ROI for healthcare spending the way we expect a reasonable return from other investments? By 2026, national health expenditures will reach $5.7

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Consequences of the First 10 Drugs Selected for Medicare’s Negotiation Program

PM360

As many in the industry now know, the Inflation Reduction Act (IRA) is the most significant reform of Medicare prescription drug coverage since the creation of Part D and has wide-ranging implications for the healthcare industry. The MFPs will be announced publicly in September 2024 and go into effect on January 1, 2026.

article thumbnail

Five points on CMS’s first ten picks for price negotiations

Clarivate

The initial list, which takes effect in 2026, has the potential to roil formularies since it includes a mix of high-volume, preferred brands and a group of high-cost specialty drugs for autoimmune conditions (psoriasis) and cancer. In both cases, a shift in formulary placement could lower prescription volumes and reduce member utilization.

article thumbnail

Key Developments from AMCP 2023 on Blockbuster Generics, Diabetes Drugs, PBM Legislation, and More

PM360

This product would be a more potent prescription version than the OTCs, Casberg notes. Starting in 2026, the provision will affect 10 Part D drugs. This increases to 15 Part D drugs in 2026, as well as 15 Part B and D drugs in 2028, and a full 20 Part B and D drugs in 2029.

article thumbnail

FDA head Califf on tighter accelerated approvals and lower drug prices at JP Morgan

Pharmaceutical Technology

FDA director Robert Califf gave his prognosis for the pharma industry at this year’s JP Morgan Healthcare Conference in San Francisco over January 9–12. Nonetheless, Cailiff expressed optimism about US innovation and adaptability in the face of these changes.

FDA 52
article thumbnail

Inflationary storm clouds will continue to buffet global pharma industry in 2023

Pharmaceutical Technology

The legislation contains several provisions to lower prescription drug costs, including allowing Medicare to negotiate the cost of selected medicines. Negotiated prices will not apply until 2026, but the selected medicines for Medicare price negotiations will be unveiled in September 2023. Free Report.

Pharma 64